LogicBio Therapeutics (NASDAQ: LOGC)
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-12-20 | ||||||
REV |
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-11-09 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of LogicBio Therapeutics (NASDAQ: LOGC) through any online brokerage.
Other companies in LogicBio Therapeutics’s space includes: Biocept (NASDAQ:BIOC), Monopar Therapeutics (NASDAQ:MNPR), Calithera Biosciences (NASDAQ:CALA), ABVC BioPharma (NASDAQ:ABVC) and Indaptus Therapeutics (NASDAQ:INDP).
The latest price target for LogicBio Therapeutics (NASDAQ: LOGC) was reported by Cantor Fitzgerald on Friday, August 12, 2022. The analyst firm set a price target for 4.00 expecting LOGC to rise to within 12 months (a possible 545.27% upside). 50 analyst firms have reported ratings in the last year.
The stock price for LogicBio Therapeutics (NASDAQ: LOGC) is $0.6199 last updated August 12, 2022, 8:00 PM UTC.
The next LogicBio Therapeutics (LOGC) dividend date is projected to be Thursday, September 1, 2022.
LogicBio Therapeutics’s FY earnings are confirmed for Wednesday, December 20, 2023.
There is no upcoming split for LogicBio Therapeutics.
LogicBio Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.